BridgeBio Pharma Net Worth 2018-2023 | BBIO
Interactive chart of historical net worth (market cap) for BridgeBio Pharma (BBIO) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. BridgeBio Pharma net worth as of April 26, 2024 is $4.66B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $4.656B | $0.009B |
| BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $15.482B | 5.59 |
| Dr Reddy's Laboratories (RDY) | India | $12.441B | 19.67 |
| Aspen Pharmacare (APNHY) | South Africa | $5.038B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $3.183B | 2.48 |
| Amphastar Pharmaceuticals (AMPH) | United States | $2.009B | 13.75 |
| Supernus Pharmaceuticals (SUPN) | United States | $1.646B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $0.447B | 0.00 |
| Generation Bio (GBIO) | United States | $0.193B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.069B | 0.00 |
| Personalis (PSNL) | United States | $0.064B | 0.00 |
| Acasti Pharma (ACST) | Canada | $0.027B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.025B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.004B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |